Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BeyondSpring Inc. (NASDAQ: BYSI).

Full DD Report for BYSI

You must become a subscriber to view this report.


Recent News from (NASDAQ: BYSI)

BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present results of the Phase 2 portion of Study 105, a prosp...
Source: GlobeNewswire
Date: May, 17 2018 07:00
BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that Lan Huang, Ph.D., Chairman, Chief Executive Officer and Co-Founder of BeyondSp...
Source: GlobeNewswire
Date: May, 07 2018 07:00
BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will present Phase 2 neutropenia clinical trial data  on its...
Source: GlobeNewswire
Date: April, 25 2018 16:30
BeyondSpring Presents Lead Asset's Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the presentation of preclinical data from the Company’s lead asset, Plin...
Source: GlobeNewswire
Date: April, 17 2018 07:00
BeyondSpring's (BYSI) CEO Lan Huang on Q4 2017 Results - Earnings Call Transcript
BeyondSpring Inc. (BYSI) Q4 2017 Earnings Conference Call April 3, 2018 08:00 AM ET Executives Susan Kim - Argot Partners LLC Lan Huang - Co-Founder, Chairman & CEO Ramon Mohanlal - Chief Medical Officer Analysts Joseph Pantginis - H.C. Wainwright & Co, LLC Jason ...
Source: SeekingAlpha
Date: April, 04 2018 17:06
BeyondSpring Files Its 2017 Annual Report on Form 20-F
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year ended Dec...
Source: GlobeNewswire
Date: April, 03 2018 16:30
BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc.  (the “Company”) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced its fourth-quarter and full-year financia...
Source: GlobeNewswire
Date: April, 03 2018 07:00
BeyondSpring appoints Edward Dongheng Liu as CFO
BeyondSpring ( BYSI ) appointed Edward Dongheng Liu as Chief Financial Officer, effective immediately. More news on: BeyondSpring Inc., Read more ...
Source: SeekingAlpha
Date: March, 28 2018 09:38
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on...
Source: GlobeNewswire
Date: March, 27 2018 16:05
BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today the appointment of Edward Dongheng Liu as Chief Financial Officer of the Company,...
Source: GlobeNewswire
Date: March, 27 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1730.0027.6130.0027.4018,791

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-146601,76337.4362Short
2018-08-1363098064.2857Short
2018-08-101,21411,93710.1701Cover
2018-08-075611,37940.6817Short
2018-08-066572,35727.8744Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BYSI.


About BeyondSpring Inc. (NASDAQ: BYSI)

Logo for BeyondSpring Inc. (NASDAQ: BYSI)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $623,875,138 - 05/14/2018
  • Issue and Outstanding: 22,530,702 - 12/31/2017

 


Recent Filings from (NASDAQ: BYSI)

Amendment to a previously filed 20-F
Filing Type: 20-F/AFiling Source: edgar
Filing Date: May, 16 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: April, 25 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: April, 03 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 21 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: January, 10 2018

 

 


Daily Technical Chart for (NASDAQ: BYSI)

Daily Technical Chart for (NASDAQ: BYSI)


Stay tuned for daily updates and more on (NASDAQ: BYSI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BYSI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BYSI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BYSI and does not buy, sell, or trade any shares of BYSI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/